Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma

Medical Oncology

Volumn 32, Issue 3, 2015, Pages

  Ge, Tianxiang ^a,b   Shen, Qiujin ^b   Wang, Ning ^b   Zhang, Yurong ^b   Ge, Zhouhong ^b   Chu, Wei ^b   Lv, Xiufang ^c   Zhao, Fengbo ^c   Zhao, Weifeng ^d   Fan, Jia ^e   Qin, Wenxin ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NANTONG MEDICAL COLLEGE   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^e FUDAN UNIVERSITY   (China)

Author keywords

Alpha fetoprotein; Diagnosis; Dickkopf 1; Hepatocellular carcinoma; Osteopontin

Indexed keywords

ALPHA FETOPROTEIN; DICKKOPF 1 PROTEIN; OSTEOPONTIN; DKK1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; AREA UNDER THE CURVE; BLOOD; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; CLINICAL TRIAL; FEMALE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTICENTER STUDY; RECEIVER OPERATING CHARACTERISTIC;

ALPHA-FETOPROTEINS; AREA UNDER CURVE; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OSTEOPONTIN; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84922455908     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0367-z     Document Type: Article

References (38)

1. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Suppl 4):5–13. doi:10.1634/theoncologist.2010-S4-05.
2. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62(6):394–9. doi:10.3322/caac.21161.
3. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38. doi:10.1016/j.jhep.2006.05.013.
4. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol. 2004;130(9):497–513. doi:10.1007/s00432-004-0572-9.
5. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361(15):1437–47. doi:10.1056/NEJMoa0901282.
6. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698–711. doi:10.1093/jnci/djn134.
7. Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology (Baltimore, MD). 1990;12(6):1420–32.
8. Bruix J, Sherman M. Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology (Baltimore, MD). 2005;42(5):1208–36. doi:10.1002/hep.20933.
9. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310(22):1427–31. doi:10.1056/NEJM198405313102204.
10. Aoyagi Y, Suzuki Y, Isemura M, Nomoto M, Sekine C, Igarashi K, et al. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer. 1988;61(4):769–74.
11. Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23(10):1541–8. doi:10.1111/j.1440-1746.2008.05395.x.
12. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–8. doi:10.1053/j.gastro.2009.04.005.
13. Ertle JM, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, et al. A combination of alpha-fetoprotein and des-gamma-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion. 2013;87(2):121–31. doi:10.1159/000346080.
14. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 1998;391(6665):357–62. doi:10.1038/34848.
15. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, et al. Kremen proteins are dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature. 2002;417(6889):664–7. doi:10.1038/nature756.
16. Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, et al. Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol. 2009;50(5):948–57. doi:10.1016/j.jhep.2008.11.020.
17. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13(8):817–26. doi:10.1016/S1470-2045(12)70233-4.
18. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979;16(4):885–93.
19. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39(4):410–33. doi:10.1053/j.seminoncol.2012.05.001.
20. Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci Off J Soc Toxicol. 2008;103(1):4–13. doi:10.1093/toxsci/kfm246.
21. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (Baltimore, MD). 2012;55(2):483–90. doi:10.1002/hep.24703.
22. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol. 2012;107(1):64–74. doi:10.1038/ajg.2011.312.
23. Huang TS, Shyu YC, Turner R, Chen HY, Chen PJ. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Syst Rev. 2013;2:37. doi:10.1186/2046-4053-2-37.
24. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology (Baltimore Md). 2009;50(3):661–2. doi:10.1002/hep.23190.
25. Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore Md). 2011;53(3):1020–2. doi:10.1002/hep.24199.
26. Block T, Mehta AS, London WT. Hepatocellular carcinoma of the liver. Cancer Biomark Sect A Dis Markers. 2010;9(1–6):375–83. doi:10.3233/CBM-2011-0165.
27. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008;57(11):1592–6. doi:10.1136/gut.2008.149062.
28. Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev. 2007;33(5):437–47. doi:10.1016/j.ctrv.2007.04.001.
29. Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 2007;67(6):2517–25. doi:10.1158/0008-5472.CAN-06-3369.
30. Sheng SL, Huang G, Yu B, Qin WX. Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem. 2009;55(9):1656–64. doi:10.1373/clinchem.2009.125641.
31. Tung EK, Mak CK, Fatima S, Lo RC, Zhao H, Zhang C, et al. Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int Off J Int Assoc Study Liver. 2011;31(10):1494–504. doi:10.1111/j.1478-3231.2011.02597.x.
32. Yang H, Chen GD, Fang F, Liu Z, Lau SH, Zhang JF, et al. Dickkopf-1: as a diagnostic and prognostic serum marker for early hepatocellular carcinoma. Int J Biol Markers. 2013;28(3):286–97. doi:10.5301/jbm.5000015.
33. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9(4):416–23. doi:10.1038/nm843.
34. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 2010;103(6):861–9. doi:10.1038/sj.bjc.6605834.
35. Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of osteopontin as a clinical cancer marker. Oncol Rep. 2011;25(2):433–41. doi:10.3892/or.2010.1106.
36. Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Nat Compr Cancer Netw JNCCN. 2009;7(4):350–91.
37. Cho HJ, Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep. 2009;11(3):206–13.
38. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010;14(8):2037–44. doi:10.1111/j.1582-4934.2010.01115.x.